Brief: HBM Says Got IND Approval Of From NMPA To Begin Phase I Clinical Trial Of B7h4x4-1Bb Bispecific Antibody
08/06/2022 11:29
June 8 (Reuters) - Hbm Holdings Ltd 2142.HK :
* GRANTED APPROVAL OF IND FROM NMPA TO COMMENCE PHASE I
CLINICAL
TRIAL OF ITS B7H4X4-1BB BISPECIFIC ANTIBODY (HBM7008) IN CHINA
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study